Professor Sun Myint
Clatterbridge Cancer Centre (Private Clinic)
Professor Sun Myint introduced Papillon in 1993 and established the first facility in the UK at Clatterbridge Cancer Centre. He has now treated over 1600 patients with Papillon which is the world largest cohort treated by non-surgical method. He collaborated with his mentor Prof Jean Pierre Gerard (Nice) and Ariane a British company to produce a new contact X-ray machine. Since 2009 he used the first prototype Papillon 50. He is now working closely with Ariane to produce a second generation Papillon Plus machine which can treat other tumour sites such as breast, skin, eye, intra oral, intra vagina and intra operative radiation therapy.
NICE has now approved the Papillon treatment for rectal cancer in patients not suitable for surgery (IPG 532). For his contributions to oncology, he was awarded Honorary Professor by University of Liverpool in 2012. He led the UK Papillon team which won the prestigious BMJ award for ‘Cancer team of the year’ in May 2018.
Rectal cancer- Do patients have a choice?
Each year 12,000 patients are diagnosed with rectal cancer in the UK. The standard of care is radical surgery. Not all patients are suitable for surgery due to advancing age and their comorbidities. The mortality and morbidity is high following surgery in elderly patients. There is increase in ageing population in the UK. Contact X-ray brachytherapy[CXB] (Papillon) will be discuss as an alternative non-surgical treatment option for patients not suitable for surgery.
EVEN MORE SEMINARS
Dr Khurum Khan University College London Hospitals
Translational research in GI Oncology- how to make progress?
Professor Noel Clarke The Christie and Salford Royal Hospitals, Manchester UK
Improving Prostate Cancer Outcomes Through Cancer Trials
Malcolm Wilson The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester
Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer